Results 121 to 130 of about 59,823 (200)

Design and Synthesis of Novel Isoflavene TANK‐Binding Kinase 1 Inhibitors With Anti‐Inflammatory Activity

ChemMedChem, Volume 21, Issue 13, 14 July 2026.
TANK‐binding kinase 1 (TBK1) is a key regulator of innate immune signalling and an emerging therapeutic target. Here, we report the design, synthesis, and biological evaluation of isoflavonoid TBK1‐modulating analogues, achieving a sixfold enhancement in inhibition of TBK1 signalling relative to the clinically relevant idronoxil (IDX) parent scaffold ...
Valerio Falasca, W. Samantha N. Jayasekara, Dominic De Nardo, Daniel S. Wenholz, Michael P. Gantier, Naresh Kumar   +5 more
wiley   +1 more source

Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data. [PDF]

J Neurooncol
Wang D, Liu X, Wang J, Zhang B, Zhai S, Xu J, Wang L, Zheng Y, Wei W, Zhou Y.   +9 more
europepmc   +1 more source

Concurrent chemoradiotherapy with temozolomide in newly pediatric diffuse intrinsic pontine glioma: clinical outcomes and safety analysis. [PDF]

Transl Pediatr
Attinà G, Maurizi P, Romano A, Talloa D, Verdolotti T, Frassanito P, Tamburrini G, Chiesa S, Mastrangelo S, Ruggiero A.   +9 more
europepmc   +1 more source

Selective blood-brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide. [PDF]

Oncoscience
Bauer JA, Sysel AM, Dunphy MJ.
europepmc   +1 more source

Correction: CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and temozolomide sensitivity. [PDF]

Cell Death Dis
Lu Z, Wang XY, He KY, Han XH, Wang X, Zhang Z, Qu XH, Chen ZP, Han XJ, Wang T.   +9 more
europepmc   +1 more source

Regression of a Non-Irradiated Lung Adenocarcinoma During Glioblastoma-Directed Chemoradiotherapy: A Case Report. [PDF]

Curr Oncol
Iwanaga M, Dotsu Y, Hiu T, Ueki N, Hirano Y, Tokito T, Morikawa T, Kaneko S, Honda N, Akagi K, Tomono H, Matsuo M, Taniguchi H, Takemoto S, Okano S, Mukae H.   +15 more
europepmc   +1 more source

Has Glioblastoma Five- and Ten-Year Survival Been Affected by New Treatment Algorithms in Population-Based Data? A Retrospective Swedish Survey Between 1958 and 2015. [PDF]

Cancers (Basel)
Milos P, Ehinger E, Visse E, Siesjö P.
europepmc   +1 more source

Statement of Retraction: SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy. [PDF]

Bioengineered
europepmc   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial. [PDF]

Target Oncol
Rubio-San-Simón A, Marshall LV, Karamouza E, André N, Abbou S, Rubino J, Nebchi S, Aerts I, Thebaud E, Brisset C, Ducassou S, Le Teuff G, Geoerger B.   +12 more
europepmc   +1 more source